Current practices for QSP model assessment: an IQ consortium survey.

Decision Making Drug Industry Modeling and Simulation Network Pharmacology

Journal

Journal of pharmacokinetics and pharmacodynamics
ISSN: 1573-8744
Titre abrégé: J Pharmacokinet Pharmacodyn
Pays: United States
ID NLM: 101096520

Informations de publication

Date de publication:
11 Aug 2022
Historique:
received: 28 04 2022
accepted: 03 06 2022
entrez: 11 8 2022
pubmed: 12 8 2022
medline: 12 8 2022
Statut: aheadofprint

Résumé

Quantitative Systems Pharmacology (QSP) modeling is increasingly applied in the pharmaceutical industry to influence decision making across a wide range of stages from early discovery to clinical development to post-marketing activities. Development of standards for how these models are constructed, assessed, and communicated is of active interest to the modeling community and regulators but is complicated by the wide variability in the structures and intended uses of the underlying models and the diverse expertise of QSP modelers. With this in mind, the IQ Consortium conducted a survey across the pharmaceutical/biotech industry to understand current practices for QSP modeling. This article presents the survey results and provides insights into current practices and methods used by QSP practitioners based on model type and the intended use at various stages of drug development. The survey also highlights key areas for future development including better integration with statistical methods, standardization of approaches towards virtual populations, and increased use of QSP models for late-stage clinical development and regulatory submissions.

Identifiants

pubmed: 35953664
doi: 10.1007/s10928-022-09811-1
pii: 10.1007/s10928-022-09811-1
pmc: PMC9371373
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32859743
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):336-339
pubmed: 30924594
CPT Pharmacometrics Syst Pharmacol. 2021 Dec;10(12):1479-1484
pubmed: 34734497
CPT Pharmacometrics Syst Pharmacol. 2019 Feb;8(2):62-76
pubmed: 30417600
CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1281-1296
pubmed: 34514745
CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):420-427
pubmed: 33793084
CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):135-146
pubmed: 29349875
CPT Pharmacometrics Syst Pharmacol. 2012 Nov 14;1:e14
pubmed: 23835796
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):344-346
pubmed: 30983120
Expert Opin Drug Discov. 2016;11(3):241-56
pubmed: 26689499
Biopharm Drug Dispos. 2021 Apr;42(4):107-117
pubmed: 33325034
CPT Pharmacometrics Syst Pharmacol. 2020 Jan;9(1):21-28
pubmed: 31652029
CPT Pharmacometrics Syst Pharmacol. 2021 Jan;10(1):18-29
pubmed: 33217169
CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):259-272
pubmed: 30667172
IEEE Trans Vis Comput Graph. 2014 Dec;20(12):1983-92
pubmed: 26356912
Clin Transl Sci. 2021 Jan;14(1):239-248
pubmed: 32822108
CPT Pharmacometrics Syst Pharmacol. 2022 Jul 20;:
pubmed: 35857704
AAPS J. 2021 Apr 30;23(3):60
pubmed: 33931790
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):340-343
pubmed: 30983158
Clin Pharmacol Ther. 2021 Nov;110(5):1147-1154
pubmed: 34658027
CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):264-289
pubmed: 34921743
Clin Pharmacol Ther. 2018 Nov;104(5):797
pubmed: 29943816
Clin Pharmacol Ther. 2018 Jul;104(1):88-110
pubmed: 29315504
Bioinformatics. 2017 Sep 15;33(18):2938-2940
pubmed: 28645171
J Investig Med. 2016 Feb;64(2):376-82
pubmed: 26911627
Clin Pharmacol Ther. 2018 Nov;104(5):798
pubmed: 30007034
Clin Pharmacol Ther. 2019 Mar;105(3):710-718
pubmed: 30350311
CPT Pharmacometrics Syst Pharmacol. 2016 Feb;5(2):43-53
pubmed: 26933515

Auteurs

Jason R Chan (JR)

Global PKPD and Pharmacometrics, Eli Lilly and Company, Indianapolis, IN, 46285, USA. jrchan@lilly.com.

Richard Allen (R)

Worldwide Research, Development and Medical, Pfizer Inc. Kendall Square, Cambridge, MA, 02139, USA.

Britton Boras (B)

Worldwide Research, Development and Medical, Pfizer Inc.,, La Jolla, CA, 92121, USA.

Antonio Cabal (A)

Eisai Inc., NJ, Nutley, USA.

Valeriu Damian (V)

GlaxoSmithKline, Collegeville, PA, 19426, USA.

Francis D Gibbons (FD)

, Takeda, Cambridge, MA, 02139, USA.

Abhishek Gulati (A)

Merck & Co. Inc., Rahway, NJ, USA.

Iraj Hosseini (I)

Genentech Inc., South San Francisco, CA, 94080, USA.

Jeffrey D Kearns (JD)

Novartis Institutes for BioMedical Research, Cambridge, MA, 02139, USA.

Ryuta Saito (R)

Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan.

Lourdes Cucurull-Sanchez (L)

GlaxoSmithKline, Stevenage, Hertfordshire, UK.

Jangir Selimkhanov (J)

Takeda Development Center Americas Inc., San Diego, CA, 92121, USA.

Andrew M Stein (AM)

Pharmacometrics, Novartis Institutes of BioMedical Research, Cambridge, MA, USA.

Kenichi Umehara (K)

Roche Pharmaceutical Research and Early Development, Basel, Switzerland.

Guanyu Wang (G)

Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Abingdon, Oxfordshire, UK.

Weirong Wang (W)

Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, LLC, Spring House, PA, 19477, USA.

Susana Neves-Zaph (S)

Data and Data Science, Translational Disease Modeling, Sanofi, USA.

Classifications MeSH